Medicare Coverage
13 articles on Medicare Coverage, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Medicare's New GLP-1 Weight-Loss Drug Program: What to Know
Medicare is launching a new pilot program to increase access to GLP-1 medications for weight loss, offering a $50 monthly copay for eligible beneficiaries. This marks a significant step in covering obesity as a medical condition.
9 min read
Most People Who Stop GLP-1 Drugs Like Ozempic Eventually Restart Treatment
A recent study presented at ENDO 2026 sheds light on the patterns of GLP-1 medication use for type 2 diabetes, revealing that while many patients stop treatment, a substantial number later restart, suggesting a more cyclical rather than permanent discontinuation.
7 min read
Ozempic, Mounjaro & More: Yale Study Exposes Risky Online GLP-1 Prescribing
New research from Yale University highlights critical gaps in the online prescribing of GLP-1 medications, raising serious concerns about patient safety and regulatory oversight.
8 min read
Medicare's $50 GLP-1 Weight Loss Drug Trial: Who Qualifies?
For many older Americans, the high cost of GLP-1 weight loss medications has been a significant barrier. Now, a new Medicare trial offers a lifeline, potentially making these life-changing drugs accessible for just $50 a month. This article breaks down what you need to know about the Medicare GLP-1 Bridge program, including who qualifies, which medications are covered, and the program's future.
8 min read
Navigating Medicare's New Path for GLP-1 Weight Loss Coverage
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
6 min read
Wegovy & Mounjaro: Navigating Medicare's New Path to Weight Loss
For years, Medicare's stance on GLP-1 medications for weight loss was a firm 'no.' However, a significant shift is underway. Discover how the new 'Bridge' program opens doors to crucial weight management tools like Wegovy and Mounjaro, and what you need to know.
6 min read
Wegovy and Zepbound on Medicare: What the $50 Co-Pay Means for Your Health
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
7 min read
Online GLP-1 Programs: Revolutionizing Medically Supervised Weight Loss
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
11 min read
Expanding Access to GLP-1 Weight-Loss Meds is Essential
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
5 min read
Weight-Loss Price Wars Upend Big Pharma's Model
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
6 min read
Medicare GLP-1 Coverage 2026: Wegovy, Zepbound Guide
Medicare is breaking its long-standing rule against covering weight loss drugs like Wegovy and Zepbound through a new GLP-1 initiative. Starting with a bridge phase in July 2026, eligible beneficiaries could pay just $50 monthly copays—if they act now. This guide explains the changes, requirements, and clinical context for GLP-1 therapy.
4 min read
GLP-1s: Understanding the Evolution of Weight-Loss Medications
Weight-loss drugs, particularly those mimicking GLP-1, have gained significant traction. This article delves into their functionality, efficacy, side effects, accessibility challenges, and the emergence of more accessible pill versions.
6 min read